Processa Pharmaceuticals (PCSA) stock: insider trades, news & valuation
Quiet
Close · Oct 9, 2026
$1.52
+12.6% on the day
-84.5% over 12 months
52-week range $1.35 – $11.03
Share price and insider trades
PCSA closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$0
Insiders buying0
Insiders selling0
Processa Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 0 sold $0 of PCSA stock on the open market.
Get emailed when insiders cluster-buy stocks like PCSA
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
PCSA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $6K | 1 | — | 0 |
| Q2 2026 | $171K | 34 | — | 0 |
| Q1 2026 | $49K | 10 | — | 0 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day2.2×Last 5 sessions
Insiders' paper profit−$90KOn all tracked purchases -40.2%
Summary
No open-market purchases or sales by Processa Pharmaceuticals, Inc. insiders were reported in the past 12 months.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 1SEC | Russell SkibstedCFO | Buy | 3,27716,689 held (+24%) | $1.93 | $6K | -21.2% | — |
| Jul 1SEC | George K NgCEO | Buy | 3,05715,492 held (+25%) | $1.93 | $6K | -21.2% | — |
| Jul 1SEC | David YoungPres. Research & Development | Buy | 2,53121,729 held (+13%) | $1.93 | $5K | -21.2% | — |
| Jul 1SEC | Wendy GuyChief Administrative Officer | Buy | 2,43614,394 held (+20%) | $1.93 | $5K | -21.2% | — |
| Jul 1SEC | Patrick LinChief Business - Strategy Off | Buy | 2,10613,113 held (+19%) | $1.93 | $4K | -21.2% | — |
| Jun 16SEC | Russell SkibstedCFO | Buy | 2,65413,412 held (+25%) | $2.22 | $6K | -31.5% | — |
| Jun 16SEC | George K NgCEO | Buy | 2,46512,435 held (+25%) | $2.22 | $5K | -31.5% | — |
| Jun 16SEC | Wendy GuyChief Administrative Officer | Buy | 2,11811,958 held (+22%) | $2.22 | $5K | -31.5% | — |
| Jun 16SEC | David YoungPres. Research & Development | Buy | 2,06719,198 held (+12%) | $2.22 | $5K | -31.5% | — |
| Jun 16SEC | Patrick LinChief Business - Strategy Off | Buy | 1,83111,007 held (+20%) | $2.22 | $4K | -31.5% | — |
| Jun 1SEC | Russell SkibstedCFO | Buy | 2,29210,758 held (+27%) | $2.57 | $6K | -40.9% | — |
| Jun 1SEC | George K NgCEO | Buy | 2,1299,970 held (+27%) | $2.57 | $5K | -40.9% | — |
| Jun 1SEC | Wendy GuyChief Administrative Officer | Buy | 1,8299,840 held (+23%) | $2.57 | $5K | -40.9% | — |
| Jun 1SEC | David YoungPres. Research & Development | Buy | 1,78617,131 held (+12%) | $2.57 | $5K | -40.9% | — |
| Jun 1SEC | Patrick LinChief Business - Strategy Off | Buy | 1,5829,176 held (+21%) | $2.57 | $4K | -40.9% | — |
| May 19SEC | Russell SkibstedCFO | Buy | 1,9848,466 held (+31%) | $2.97 | $6K | -48.8% | — |
| May 19SEC | George K NgCEO | Buy | 1,8433,979 held (+86%) | $2.97 | $5K | -48.8% | — |
| May 19SEC | George K NgCEO | Buy | 1,8437,841 held (+31%) | $2.97 | $5K | -48.8% | — |
| May 19SEC | Sian BigoraChief Development Officer | Buy | 1,9717,481 held (+36%) | $2.71 | $5K | -43.9% | — |
| May 19SEC | Wendy GuyChief Administrative Officer | Buy | 1,5838,011 held (+25%) | $2.97 | $5K | -48.8% | — |
| May 19SEC | David YoungPres. Research & Development | Buy | 1,54515,345 held (+11%) | $2.97 | $5K | -48.8% | — |
| May 19SEC | Patrick LinChief Business - Strategy Off | Buy | 1,3697,594 held (+22%) | $2.97 | $4K | -48.8% | — |
| May 1SEC | Russell SkibstedCFO | Buy | 2,1906,498 held (+51%) | $2.69 | $6K | -43.5% | — |
| May 1SEC | George K NgCEO | Buy | 2,0346,013 held (+51%) | $2.69 | $5K | -43.5% | — |
| May 1SEC | Sian BigoraChief Development Officer | Buy | 1,9867,496 held (+36%) | $2.69 | $5K | -43.5% | — |
| May 1SEC | Wendy GuyChief Administrative Officer | Buy | 1,7486,441 held (+37%) | $2.69 | $5K | -43.5% | — |
| May 1SEC | David YoungPres. Research & Development | Buy | 1,70613,813 held (+14%) | $2.69 | $5K | -43.5% | — |
| May 1SEC | Patrick LinChief Business - Strategy Off | Buy | 1,5116,236 held (+32%) | $2.69 | $4K | -43.5% | — |
| Apr 30SEC | George K NgCEO | Buy | 1,8433,979 held (+86%) | $2.97 | $5K | -48.8% | — |
| Apr 30SEC | George K NgCEO | Buy | 2,136new position | $2.54 | $5K | -40.2% | — |
| Apr 17SEC | Russell SkibstedCFO | Buy | 1,9844,308 held (+85%) | $2.97 | $6K | -48.8% | — |
| Apr 17SEC | George K NgCEO | Buy | 1,8435,492 held (+51%) | $2.97 | $5K | -48.8% | — |
| Apr 17SEC | Sian BigoraChief Development Officer | Buy | 1,7995,510 held (+48%) | $2.97 | $5K | -48.8% | — |
| Apr 17SEC | Wendy GuyChief Administrative Officer | Buy | 1,5834,693 held (+51%) | $2.97 | $5K | -48.8% | — |
| Apr 17SEC | David YoungPres. Research & Development | Buy | 1,54512,107 held (+15%) | $2.97 | $5K | -48.8% | — |
| Apr 17SEC | Patrick LinChief Business - Strategy Off | Buy | 1,3694,725 held (+41%) | $2.97 | $4K | -48.8% | — |
| Apr 2SEC | James R NealDirector | Buy | 789818 held (+2721%) | $2.54 | $2K | -40.2% | — |
| Apr 1SEC | Russell SkibstedCFO | Buy | 2,324new position | $2.54 | $6K | -40.2% | — |
| Apr 1SEC | Khoso BaluchDirector | Buy | 2,2692,325 held (+4052%) | $2.54 | $6K | -40.2% | — |
| Apr 1SEC | George K NgCEO | Buy | 2,1363,649 held (+141%) | $2.54 | $5K | -40.2% | — |
| Apr 1SEC | Sian BigoraChief Development Officer | Buy | 2,1073,711 held (+131%) | $2.54 | $5K | -40.2% | — |
| Apr 1SEC | Geraldine PannuDirector | Buy | 2,0722,188 held (+1786%) | $2.54 | $5K | -40.2% | — |
| Apr 1SEC | Wendy GuyChief Administrative Officer | Buy | 1,8543,110 held (+148%) | $2.54 | $5K | -40.2% | — |
| Apr 1SEC | David YoungPres. Research & Development | Buy | 1,81010,562 held (+21%) | $2.54 | $5K | -40.2% | — |
| Apr 1SEC | Patrick LinChief Business - Strategy Off | Buy | 1,6033,356 held (+91%) | $2.54 | $4K | -40.2% | — |
Insiders at Processa Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| George K NgCEO | $55K | — | Jul 1, 2026 | — |
| Russell SkibstedCFO | $42K | — | Jul 1, 2026 | — |
| Wendy GuyChief Administrative Officer | $33K | — | Jul 1, 2026 | — |
| David YoungPres. Research & Development | $32K | — | Jul 1, 2026 | — |
| Patrick LinChief Business - Strategy Off | $28K | — | Jul 1, 2026 | — |
| Sian BigoraChief Development Officer | $21K | — | May 19, 2026 | — |
| Khoso BaluchDirector | $6K | — | Apr 1, 2026 | — |
| Geraldine PannuDirector | $5K | — | Apr 1, 2026 | — |
| James R NealDirector | $2K | — | Apr 2, 2026 | — |
PCSA stock: common questions
Are Processa Pharmaceuticals, Inc. insiders buying PCSA stock?
In the past 12 months, 0 insiders reported open-market purchases of PCSA worth $0. The latest was CFO Russell Skibsted bought $6K of PCSA at $1.93 — largest purchase by this insider in our records; raises the stake by 24%.
Are Processa Pharmaceuticals, Inc. insiders selling PCSA stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is PCSA's 52-week range?
Over the past year PCSA has traded between $1.35 and $11.03. It last closed at $1.52 on Oct 9, 2026.